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Dithioate analogsAbstract Anti-cancer effect and mechanism of cell death were investigated in a battery of ﬁve
thalidomide analogs containing one sulfur atom 2 or two sulfur atoms 3–6 and were compared with
thalidomide 1 activity. The cytotoxic effect of thalidomide analogs 2–6 against Hep-G2, 1301, and
HCT-116 cells was estimated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (MTT) assay. Apoptosis and necrosis cell percentage was stained by ethidium bromide and
acridine orange, DNA fragmentation, inhibition of histone deacetylase (HDAC), and total caspases
were assayed by universal procedures and kits. We report here for the anti-cancer activity of thalid-
omide dithiocarbamate analog 3 and thalidomide dithioate analog 5 against Hep-G2 and HCT-116
cells, which was more cytotoxic than thalidomide itself, and that the cytotoxicity was associated with
DNA fragmentation and was due to apoptosis and not necrosis. Moreover, we suggest that the cell
death pathway is evoked by thalidomide dithiocarbamate analog 3 and thalidomide dithioate analog
5 in human hepatocellular carcinoma cells through multiple consequences that trigger apoptotic cell
death; involving the enhancement of DNA fragmentation, the activation of caspases, and the induc-
tion of histone acetylation. In conclusion, thalidomide dithiocarbamate analog 3 and thalidomide
dithioate analog 5 are promising anti-cancer agents more than thalidomide.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology.1. Introduction
Thalidomide 1 has been introduced to the pharmaceutical mar-
ket, as a quite successful sedative, in 1956. However, in 1961, it
was withdrawn from the market due to its unsuspected terato-
genic activity [1]. In the recent decade, thalidomide was re-
evaluated and has attracted signiﬁcant attention due to
its selective inhibitory activity to tumor necrosis factor-a
(TNF-a) [2], which is a clinically important activity against
66 M.A.H. Zahran et al.serious diseases such as rheumatoid arthritis, AIDS, leprosy,
Crohn’s disease, and various cancers [3]. Thus, in 1998, Thalid-
omide has received FDA approval for the treatment of ery-
thema nodosum leprosum (ENL) [4]. A distinct and clear
potent antitumor activity of a series of novel isosteric thalido-
mide analogs, which were designed and synthesized was
revealed in our previous study. N-Methylthiomethyl thalido-
mide 2, thalidomide dithiocarbamate analogs 3, 4 and 6 and
thalidomide dithioate analog 5 were the most potent antitumor
analogs compared to thalidomide itself [5,6].
The four selected thalidomide dithiocarbamate and dithio-
ate analogs 3, 4, 5, and 6 possessed a high signiﬁcant reduction
in tumor volume (T.V.), antimitotic, apoptotic and necrotic
activities against solid tumor [5,6]. The antioxidative activity
of these compounds as the level of hepatic lipid peroxidation
was decreased and levels of antioxidant enzymes like superox-
ide dismutase (SOD) and catalase were elevated. The selected
analogs also demonstrated proapoptotic activity by progres-
sive increase of Fas-L immunostaining expression compared
with tumors treated with thalidomide as well as the untreated
one. Moreover, the selected analogs showed a reduction in
Ki67 protein and vascular endothelial growth factor (VEGF)
staining in tumor cells from treated-animals [5,6].
Despite their encouraging and promising results, their
mode of actions is still indistinct. Drawing inspiration from
these results, we extend our previous work for better under-
standing of the mechanisms of action of these novel com-
pounds shown in Fig. 1 and more investigation on the effect
of increasing the sulfur content in the thalidomide analogs as
antitumor compounds.
2. Materials and methods
2.1. Cell culture
Three human cell lines were used in testing anti-cancer activity
including: lymphoblastic leukemia (1301 cells, T-lymphocytes),
a generous gift from The Training Center of DakoCytomation,
Elly, UK), hepatocellular carcinoma (Hep-G2) and colon car-
cinoma (HCT-116) (ATCC, VA, USA). Cells were routinely
cultured at 37 C in humidiﬁed air containing 5% CO2 in
DMEM (Dulbecco’s Modiﬁed Eagle’s Medium), which was
supplemented with 10% fetal bovine serum (FBS), 100 units/
ml penicillin G sodium, 100 units/ml streptomycin sulfate,
2 mM L-glutamine and 250 ng/ml amphotericin B. Monolayer
cells were harvested by trypsin/EDTA treatment. All culture
material was obtained from Cambrex BioScience (Copenha-
gen, Denmark), and all chemicals were from Sigma (USA).
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Figure 1 Thalidomide 1 and its sulfur analogs 2–6.(DMSO, 99.9%, HPLC grade) and then diluted into 1000-fold
for experiments. In all cellular experiments, results were com-
pared with DMSO-treated cells. Compound dilutions were
endotoxin free as examined by endotoxin using Pyrogent
Ultra gel clot assay. All experiments were repeated four times,
unless mentioned, and the data were represented as
(mean ± S.D.).
2.2. Cytotoxicity assay
The cytotoxic effect of thalidomide analogs 2–6 against Hep-
G2, 1301, and HCT-116 cells was estimated by the 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assay [7]. In metabolically active cells, MTT (a yellow
tetrazolium salt) is reduced by mitochondrial dehydrogenases
into insoluble purple formazan crystals that were solubilized
by the addition of a detergent [8]. Cells (5 · 104 cells/well) were
incubated with various concentrations of the compound at
37 C in a FBS-free medium, before submitting to MTT assay.
The absorbance was measured with an ELISA reader (BioRad,
Mu¨nchen, Germany) at 570 nm. The relative cell viability was
determined by the amount of MTT converted to the insoluble
formazan salt. The data are expressed as the mean percentage
of viable cells as compared to the respective control cultures
treated with the solvent. The half maximal growth inhibitory
concentration IC50 values were estimated from the line equa-
tion of the dose–dependent curve of each compound.2.3. Apoptosis and necrosis staining
The type of the cell death in Hep-G2 cells was investigated in
the treated and untreated cells using acridine orange/ethidium
bromide staining. In brief, the cells were plated at glass slides
and treated with IC50 of each compound and incubated for
12 h. A mixture of 100 lg/ml acridine orange and 100 lg/ml
ethidium bromide was prepared in PBS. The cell uptake of
the stain was monitored under a ﬂuorescence microscope,
and the apoptotic, necrotic, and viable cells were counted
[9,10].2.4. DNA fragmentation
Hep-G2 cells were treated with 30% of IC50 of each compound
for 24 h. DNA fragmentation was essentially assayed as
reported previously [11]. Brieﬂy, the pellets of the treated
and untreated Hep-G2 cells were re-suspended in 250 ll
10 mM Tris, 1 mM EDTA, pH 8.0 (TE-buffer), and incubated
with an additional volume lysis buffer (5 mM Tris, 20 mM
EDTA, pH 8.0, 0.5% Triton X-100) for 30 min at 48 C. After
lysis, the intact chromatin (pellet) was separated from DNA
fragments (supernatant) by centrifugation for 15 min at
13,000g. Pellets were re-suspended in 500 ll TE-buffer and
samples were precipitated by adding 500 ll of 10% trichloro-
acetic acid at 48 C. Samples were pelleted at 4000 rpm for
10 min and the supernatant was removed. After addition of
300 ll of 5% trichloroacetic acid, samples were boiled for
15 min. DNA contents were quantiﬁed using the diphenyl-
amine reagent [9]. The percentage of DNA fragmented was
calculated as the ratio of the DNA content in the supernatant
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The activity of HDAC was measured in Hep-G2 cells, using a
colorimetric assay kit (BioVision, Mountain View, kit No.
K331-100). Cells were treated with 30% of IC50 of each com-
pound for 24 h. The procedure involves the use of the HDAC
colorimetric substrate (Boc-Lys(Ac)-pNA), which comprises
an acetylated lysine side chain and is incubated with a sample
containing nuclear extract. Deactivation sensitizes the sub-
strate, and treatment with the lysine developer produces a chro-
mophore, which can be analyzed using a colorimetric plate
reader. HeLa cell nuclear extract was used as a positive control.
A standard curve was prepared using the known amount of the
deacetylated standard (Boc-Lys-pNA) included in the kit [13].
A similar volume of control sample was added to 100 ng/ml tri-
chostatin A (TSA), as a known inhibitor of HDAC activity.0 50 100 150
1
Toxicity (IC50, µg/ml)











l)2.6. Evaluation of caspases activity
Hep-G2 cells were treated with 30% of IC50 of each compound
for different time points. The lysates of the treated and
untreated Hep-G2 cells were submitted to total caspases kit
according to the manufacturer’s instructions. Red Multi-Cas-
pase Staining Kit (#PK-CA577-K190), PromoKine, Heidel-
berg, Germany was used for an analysis of total caspases in
a black microtiter plate with ﬂuorescence plate reader at
Ex. = 540 nm and Em. = 570 nm. The assay utilizes the cas-
pase family inhibitor VAD-FMK conjugated to sulfo-rhoda-
mine (Red-VAD-FMK) as the ﬂuorescent in situ marker. A
comparison between the ﬂuorescence readings of the treated
sample and the untreated cells allows determination of the fold












 (2.7. Statistical analysis
All values were expressed at the mean ± S.D. of four measure-
ments. Data were statistically analyzed using Statistical Package
for Social Scientists (SPSS) 10.00 for windows (SPSS Inc., Chi-
cago, USA). Student’s unpaired t-test as well as a one-way anal-
ysis of variance (ANOVA) test was used to detect statistical
signiﬁcance.P valuemore than 0.05was considered insigniﬁcant.
2 4 6
Figure 2 (A) The cytotoxic effect of thalidomide and its analogs
2–6 on different human cancer cell lines including Hep-G2 cells
(gray bars), HCT-116 cells (white bars), and 1301 cells (black bars),
as measured by MTT assay. The results are represented as IC50
values (lg/ml, mean ± S.D., n= 4). (B) The proliferative effect of
thalidomide analogs 2, 4, and 6 on 1301 cells (T-lymphocytes), as
measured byMTT assay. The results are represented as the number
of folds of control (mean ± S.D., n= 4).3. Results and discussion
Exploring the cytotoxic effect of different doses of thalidomide
analogs 2–6 on the solid tumor cell lines Hep-G2 and HCT-116
and the hematopoietic tumor cell line 1301 using MTT assay, a
metabolic cytotoxicity assay, indicated that all tested com-
pounds possessed variable degrees of cytotoxicity against
Hep-G2 and HCT-116 cells, however thalidomide and its ana-
logs 3 and 5 exhibited a high cytotoxic effect against both cell
lines (IC50 < 20 lg/ml) and thalidomide dithiocarbamate ana-
log 5 was the most cytotoxic compound as concluded from its
low IC50 values as shown in Fig. 2A. On the other hand, sub-
mission of hematopoietic tumor cells; 1301 cells, to MTT assay
revealed that only thalidomide and its analogs 3 and 5 had
cytotoxic effect in the following order 3> 1> 5, as concluded
from their IC50 values (Fig. 2A, while thalidomide analogs 2, 4,
and 6 induced the proliferation of 1301 cells (T-lymphocytes)in a dose dependant manner up to 3.05-folds of control at a
dose of 40 lg/ml for methylthiomethylthalidomide 2
(Fig. 2B). This ﬁnding suggested that thalidomide analogs 2,
4, and 6 are immunostimulant agents that can drastically
induce T-lymphocyte proliferation; a suggestion that needs
to be explored further. The original chemical structure of tha-
lidomide is known as a selective agent that kills cancer cells,
but induces T cell proliferation [14]. Sun et al. [15], indicated


































Figure 3 (A) The effect of thalidomide and its analogs 2–6 on
the % of DNA fragmentation in Hep-G2 cells, compared with
vehicle-treated cells. The amount of fragmented DNA was
determined with the diphenylamine reaction (mean ± S.D.,
n= 4). (B) Analysis of cell death type (apoptosis and necrosis)
in Hep-G2 cells treated with the cytotoxic thalidomide and its
analogs 2, 3, and 5 as monitored by ethidium bromide/acridine
orange staining (mean ± S.D., n= 4). The percentage was
calculated among the total dead cells population only (the living
cells were excluded).
68 M.A.H. Zahran et al.that thalidomide can inhibit the proliferation of the human
hepatoma SMMC-7721 cells in vitro. They suggested from
their ﬁndings that the induction of apoptosis and inhibition
of angiogenesis may possibly be two mechanisms for its anti-
cancer action [15].
A previous in vitro study also revealed the thalidomide
embryotoxicity in the embryonic stem cell test based on human
induced pluripotent stem cells [16], while due to the known cell
speciﬁcity of thalidomide, another study reported that the treat-
ment with 10 lg/ml thalidomide to human myeloid KBM-5 cells
for 24 h resulted in only 7% of cell viability inhibition [17]. Wang
et al. [18], prepared 5 nitric oxide-donating thalidomide analogs
that exhibited a cytotoxic effect against three human tumor cell
lines (HepG2, lung cancer A549 cells, and prostate cancer PC-3
cells) stronger than that of 5-ﬂuorouracil. They noticed that this
cytotoxic activity is closely related to the type of NO donors, and
the length of the spacers connecting to NO donors.
Cell death is generally classiﬁed into two large categories:
apoptosis, representing ‘‘active’’ programed cell death, and
necrosis, representing ‘‘passive’’ cell death without (known)
underlying regulatory mechanisms, both are distinguished by
well deﬁned morphological and biochemical features. Necrosis
is characterized by cell swelling, disruption and rapid disinte-
gration of the cell membrane [19]. In contrast, during apopto-
sis the cells undergo nuclear and cytoplasmic shrinkage, the
chromatin is condensed and fragmented, and the cells are
ﬁnally broken into multiple membrane-surrounded bodies
(apoptotic bodies) [20]. In the consequences of the high cyto-
toxic effect of the compounds against Hep-G2 cells, we ﬁnd
that the degree of DNA fragmentation, which was assayed
by diphenylamine was induced dramatically by most of the
tested compounds (Fig. 3A), thalidomide dithiocarbamate
analog 3 and thalidomide dithioate analog 5 were the most
DNA damaging agents (Fig. 3A).
To investigate the type of cell death (apoptosis or necrosis)
induced in Hep-G2 cells after treating with the cytotoxic thalid-
omide and its analogs 2, 3, and 5, we used acridine orange/ethi-
dium bromide staining to distinguish between apoptotic,
necrotic, and viable cells. The counting indicated that in
untreated cells the range of apoptotic and necrotic cell number
was 4–8%, and 1–4%, respectively. On the other hand, the test
compounds led to a signiﬁcant dose dependant induction of
apoptosis (P< 0.01–0.001), where the cells had mainly con-
densed chromatin (Fig. 3B) and there was a low population per-
centage of the necrotic cells (Fig. 3B). Sun et al. [15], reported
that thalidomide treatment resulted in a ladder pattern of
DNA fragments in the human hepatoma SMMC-7721 cells
and the cell nuclei were condensed and fragmented.
Gene transcription from DNA, which is tightly bound to
the nucleosome core (histone proteins), is suppressed due to
decreased accessibility of transcription factors (e.g. NF-jB)
to their DNA binding motifs [21]. Acetylation of lysine resi-
dues in the N-terminal tails of the core histones results in
uncoiling of the DNA, allowing increased accessibility for
transcription factor binding [22]. The dynamic process of
acetylation is reversible and is regulated by two families of pro-
teins: the histone acetyltransferase and the HDAC [21].
HDACs remove the acetyl moieties from the e-acetamido
groups of lysine residues of histones, causing rewinding of
DNA and hence silencing gene transcription. It has been
reported that HDACs play an essential role in the regulation
of cell proliferation and apoptosis [23].To determine if decreased deacetylation is involved in net
increased DNA fragmentation and apoptosis in thalidomide
analog-treated Hep-G2 cells, we measured HDAC activity
using the substrate Boc-Lys(Ac)-pNA and a colorimetric
detection. TSA was used as a known inhibitor of HDAC activ-
ity. TSA addition to the control inhibited 53.9% of HDAC
activity (Fig. 4A), while the treatment with different com-
pounds led to a drastic decline in HDAC activity to the follow-
ing order 5> 3> 1> 2> 6> 4 (P< 0.05–0.001) of the
control activity (Fig. 4A), which means that there is an induc-






























































Figure 4 (A) The inhibitory effect of thalidomide and its analogs
2–6 against HDAC activity of Hep-G2 cells. The data were
compared with the HDAC activity of the control cells pellet that
was treated with TSA (100 ng/ml), as a known inhibitor. The
results are represented as the percentage of inhibition of HDAC
(mean ± S.D., n= 4). (B) Effect of thalidomide dithiocarbamate
analog 3 and thalidomide dithioate analog 5 on the activity of total
caspases activity of Hep-G2 cells after different incubation times.
Data are represented as folds of control (mean ± S.D., n= 4).
Thalidomide dithiocarbamate and dithioate derivatives 69the histones that form the nucleosome core around which
DNA is coiled may cause unwinding of condensed chromatin
[24]. Decondensation of the chromatin allows access of tran-
scription factors to consensus sites on DNA, leading to the
transcription of inﬂammatory mediators thereby enhancing
the inﬂammatory response [25,26].
The HDAC inhibitors are classiﬁed as second-generation
proteasome inhibitors such as heat shock protein 90 inhibitors,
2-methoxyestradiol, histone deacetylase, ﬁbroblast growth fac-
tor receptor 3 inhibitors, insulin-like growth factor 1 receptor
inhibitors, that all can treat multiple myeloma [27]. A previous
study reported that a series of hydroxamic acid derivatives bear-
ing a cyclic amide/imide group as a linker and/or cap structure,prepared during structural development studies based on thalid-
omide showed class-selective potent HDAC-inhibitory activity
[28]. They also reported that the structure–activity relationship
studies revealed that the steric character of the substituent intro-
duced at the cyclic amide/imide nitrogen atom, the presence of
the amide/imide carbonyl group, the hydroxamic acid structure,
the shape of the linking group, and the distance between the
zinc-binding hydroxamic acid group and the cap structure are
all important for HDAC-inhibitory activity and class selectivity
[28]. Podhorecka et al. [29], reported that thalidomide led to a
modest increase in the phosphorylation of histone H2AX on
Ser139 (gammaH2AX), reporter of DNA damage, but they
found that thalidomide did not affect the expression of activated
caspase-3 in ex vivo short-term cell cultures of peripheral blood
cells from newly diagnosed untreated patients.
Caspases are cysteine proteases produced as inactive zymo-
gens that cleave their substrates at aspartic acid residues
contained within a tetrapeptide recognition motif. Activation
of initiator caspases (procaspase-8, -9 and -10) leads to the pro-
teolytic activation of downstream effector caspases (caspase-3,
-6 and -7) that cleave speciﬁc substrates [30]. DNA fragmenta-
tion is due to cleavage and inactivation of ICAD, the initiator
of CAD (caspase-activated DNase). In addition, the activation
of several kinases by caspase cleavage contributes to the mem-
brane remodeling and active blebbing observed in apoptotic
cells [31]. Due to promising activities of thalidomide dithiocar-
bamate analog 3 and thalidomide dithioate analog 5 as cyto-
toxic, DNA fragmentation and apoptosis inducers and
HDAC inhibitors we investigated the possible involvement of
caspase activation of these activities, total caspase was assayed
through time and revealed that there was a signiﬁcant time-
dependent increase in the caspase level in Hep-G2 cells
(P< 0.01), when treated with either of thalidomide dithiocar-
bamate analog 3 and thalidomide dithioate analog 5 (Fig. 4B).
Accordingly, the induced-apoptosis is associated with an
induced activation of the net caspases.
The thalidomide analogs 3, 4, 5 and 6, containing two sulfur
atoms, are more potent than the N-methylthiomethyl thalido-
mide 2with only one sulfur atom, whichmeans that the increase
in the sulfur content, enhances the anti-tumor activity of these
analogs. On the other hand, thalidomide analogs 3 and 5 are
more potent than 4 and 6. On structural bases both thalidomide
analogs 3 and 5 are almost identical except the CH2–CH2 linker
in dithiocarbamate 3, which links the dithiocarbamate group
and the pipridinyl moiety, but in dithioate analog 5 the dithio
ester group is directly connected to the pipridinyl moiety. This
suggests that the activity might refer to the efﬁcacious chelation
of dithiocarbamate 3 (Thalidomide–CH2–S–CS–NH–CH2–
CH2–N pipridinyl moiety) compared with the chelation of
dithioate 5 (Thalidomide–CH2–S–CS–N pipridinyl moiety).
Thus, it is clear that the chelation efﬁciency increases through
the binding capability between the DNA and the dithiocarba-
mate group in analog 3 rather than the dithioate in analog 5
due to the presence of hydrogen atom of the imine nitrogen that
belongs to the dithiocarbamate group.
As reported recently, treatment with thalidomide resulted in
the apoptosis of mouse breast cancer cells in a time- and dose-
dependent manner as demonstrated by caspase-3 enzyme activ-
ity [32]. Sun et al. [15], reported that thalidomide treatment led
to an elevation of the apoptosis rate and to a dose-dependent
induction in caspase-3 in the human hepatoma SMMC-7721
cells. On the other hand, Keller et al. [33], reported that thalid-
70 M.A.H. Zahran et al.omide inhibited the activity and the activation of caspase-1,
which is required for unconventional protein secretion of pro-
inﬂammatory cytokines such as IL-1 and the proangiogenic
ﬁbroblast growth factor 2. The authors suggested that the latter
ﬁnding implicated that the pharmacological activity is exerted
by a metabolite of thalidomide [33]. Further investigation,
designing and synthesis of a novel thalidomide as well as
phthalimide dithiocarbamate analogs are now under consider-
ation in order to reveal the mechanism of action and under-
standing the role of each part (phthalimide part and
glutarimide part) constituting the thalidomide molecule.
Taken together, we report here the anti-cancer activity of
thalidomide dithiocarbamate analog 3 and thalidomide dithio-
ate analog 5 against Hep-G2 and HCT-116 cells, which was
more cytotoxic than thalidomide itself and that cytotoxicity
was associated with DNA fragmentation and was due to apop-
tosis and not necrosis. Moreover, we suggest that the cell death
pathway is evoked by thalidomide dithiocarbamate analog 3
and thalidomide dithioate analog 5 in human hepatocellular
carcinoma cells through multiple consequences that trigger
apoptotic cell death; involving the enhancement of DNA frag-
mentation, the activation of caspases, and the induction of his-
tone acetylation.
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